Sage Mountain Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.3K Hold
75
﹤0.01% 290
2026
Q1
$12.7K Hold
75
﹤0.01% 270
2025
Q4
$12.7K Hold
75
﹤0.01% 550
2025
Q3
$10.8K Hold
75
﹤0.01% 537
2025
Q2
$9.49K Sell
75
-60
-44% -$7.37K ﹤0.01% 485
2025
Q1
$17.3K Buy
135
+60
+80% +$8.14K ﹤0.01% 460
2024
Q4
$9.92K Hold
75
﹤0.01% 464
2024
Q3
$10.9K Hold
75
﹤0.01% 472
2024
Q2
$10.3K Hold
75
﹤0.01% 409
2024
Q1
$10.3K Hold
75
﹤0.01% 389
2023
Q4
$10.2K Hold
75
﹤0.01% 333
2023
Q3
$9.17K Hold
75
﹤0.01% 333
2023
Q2
$9.52K Hold
75
﹤0.01% 325
2023
Q1
$9.69K Hold
75
﹤0.01% 308
2022
Q4
$9.85K Hold
75
﹤0.01% 267
2022
Q3
$9K Hold
75
﹤0.01% 351
2022
Q2
$9K Hold
75
﹤0.01% 588
2022
Q1
$10K Hold
75
﹤0.01% 603
2021
Q4
$11K Hold
75
﹤0.01% 665
2021
Q3
$12K Hold
75
﹤0.01% 559
2021
Q2
$12K Hold
75
﹤0.01% 512
2021
Q1
$11K Hold
75
﹤0.01% 447
2020
Q4
$11K Buy
+75
New +$10.7K ﹤0.01% 258

Other funds holding IBB

Sage Mountain Advisors's IBB Position: Q2 2026 in Review

Sage Mountain Advisors held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 75 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #290.

Sage Mountain Advisors first reported a position in IBB in Q4 2020 and has held it in 23 quarters since. The position peaked at $17.3K in Q1 2025. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Sage Mountain Advisors held 75 shares of iShares Biotechnology ETF worth $14.3K as of Q2 2026.
  • Sage Mountain Advisors left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Sage Mountain Advisors's portfolio in Q2 2026, its #290 holding.
  • Sage Mountain Advisors first reported a position in iShares Biotechnology ETF in Q4 2020 and has held it in 23 quarters since.
  • Sage Mountain Advisors's iShares Biotechnology ETF position peaked at $17.3K in Q1 2025.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Sage Mountain Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.